| DESCRIPTION | - AGNEW, Chem Intl. Ed. Engl., (19940000), vol. 33, pages 183 - 186 | - |
| DESCRIPTION | - AGUS et al., Cancer Cell, (20020000), vol. 2, pages 127 - 37 | - |
| DESCRIPTION | - AJANI, J, The Oncologist, (20050000), vol. 3, pages 49 - 58 | - |
| DESCRIPTION | - ALLISON et al., Pro Am Soc Clin Oncol, (20030000), vol. 22, page 197 | - |
| DESCRIPTION | - AMLER et al., J Clin Oncol, (20080000), vol. 26, page 5520 | - |
| DESCRIPTION | - BANG et al., Lancet, (20100000), vol. 376, no. 9742, pages 687 - 97 | - |
| DESCRIPTION | - BARBAS et al., Proc Nat. Acad. Sci, (19940000), vol. 91, pages 3809 - 3813 | - |
| DESCRIPTION | - BASELGA et al., "ASCO Annual Meeting Proceedings Part I", J Clin Oncol, (20070620), vol. 2007, no. 18S, page 1004 | - |
| DESCRIPTION | - BASELGA et al., J. Clin. Oncol., (19960000), vol. 14, pages 737 - 744 | - |
| DESCRIPTION | - BASELGA et al., "J Clin Oncol", ASCO Annual Meeting Proceedings, (20070620), vol. 25, no. 18, page 1004 | - |
| DESCRIPTION | - BELLA et al., J. Clin. Oncol., (20080520), vol. 26 | - |
| DESCRIPTION | - BRAY et al., Int. J. Cancer, (20050000), vol. 113, pages 977 - 90 | - |
| DESCRIPTION | - CAMPIGLIO et al., J. Cell Biochem, (19990000), vol. 73, pages 522 - 32 | - |
| DESCRIPTION | - CARLSON et al., J Natl Compr Cane Netw, (20060000), vol. 3, pages 51 - 22 | - |
| DESCRIPTION | - CARTER et al., PNAS, (19920000), vol. 89, pages 4285 - 4289 | - |
| DESCRIPTION | - CARTER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, page 4285 | - |
| DESCRIPTION | - CATALANO et al., Clin Rev OncollHematol, (20050000), vol. 54, pages 209 - 41 | - |
| DESCRIPTION | - CHO et al., Nature, (20030000), vol. 421, pages 756 - 760 | - |
| DESCRIPTION | - CHOTHIA et al., J. Mol. Biol., (19870000), vol. 196, pages 901 - 917 | - |
| DESCRIPTION | - CUNNINGHAM et al., Annals of Oncology, (20050000), vol. 1, pages 22 - 3 | - |
| DESCRIPTION | - DU BOIS et al., Cancer, (20090000), vol. 115, pages 1234 - 1244 | - |
| DESCRIPTION | - ERRATUM, Mol Cell Biol, (19960000), vol. 16, page 735 | - |
| DESCRIPTION | - FRANKLIN et al., Cancer Cell, (20040000), vol. 5, pages 317 - 328 | - |
| DESCRIPTION | - GARRETT et al., Mol. Cell., (20030000), vol. 11, pages 495 - 505 | - |
| DESCRIPTION | - "Genebank", Database accession no. X03363 | - |
| DESCRIPTION | - GEYER et al., N Engl J Med, (20060000), vol. 355, pages 2733 - 2743 | - |
| DESCRIPTION | - GIANNI et al., Cancer Research, (20101200), vol. 70, no. 24 | - |
| DESCRIPTION | - HARARIYARDEN, Oncogene, (20000000), vol. 19, pages 6102 - 14 | - |
| DESCRIPTION | - HARRIS et al., J. Chromatography, B, (20010000), vol. 752, pages 233 - 245 | - |
| DESCRIPTION | - HAWKINS et al., J. Mol. Biol., (19920000), vol. 226, pages 889 - 896 | - |
| DESCRIPTION | - HUDZIAK et al., Proc. Natl. Acad. Sci. USA, (19870000), vol. 84, pages 7159 - 7163 | - |
| DESCRIPTION | - INOUE et al., Post grad Med J, (20050000), vol. 81, pages 419 - 24 | - |
| DESCRIPTION | - JACKSON et al., J. Immunol., (19950000), vol. 154, no. 7, pages 3310 - 2004 | - |
| DESCRIPTION | - JOENSUU et al., NEJM, (20060000), vol. 354, no. 18, pages 1851 - 1852 | - |
| DESCRIPTION | - JOHNS et al., J. Biol. Chem., (20040000), vol. 279, no. 29, pages 30375 - 30384 | - |
| DESCRIPTION | - KANG YKANG WKSHIN DB et al., J Clin Oncology, (20060000), vol. 24 | - |
| DESCRIPTION | - KELLEY et al., J Clin Epidemiol, (20030000), vol. 56, pages 1 - 9 | - |
| DESCRIPTION | - KIM TWKANG YKAHN JH et al., Ann Oncol, (20020000), vol. 13, pages 1893 - 8 | - |
| DESCRIPTION | - KOHLER et al., Nature, (19750000), vol. 256, page 495 | - |
| DESCRIPTION | - KOIZUMI WKURIHARA MSASAI T et al., Cancer, (19930000), vol. 72, pages 658 - 62 | - |
| DESCRIPTION | - KRAUS et al., PNAS (USA), (19890000), vol. 86, pages 9193 - 9197 | - |
| DESCRIPTION | - LACAVE AJBARON FJANTON LM et al., Ann Oncol, (19910000), vol. 2, pages 751 - 754 | - |
| DESCRIPTION | - LEE-HOEFLICH et al., Cancer Res, (20080000), vol. 68, pages 5878 - 87 | - |
| DESCRIPTION | - MALIK et al., Pro Am Soc Cancer Res, (20030000), vol. 44, pages 176 - 7 | - |
| DESCRIPTION | - MARKS et al., Bio/Technology, (19920000), vol. 10, pages 779 - 783 | - |
| DESCRIPTION | - MARTIN et al., NEJM, (20050000), vol. 352, no. 22, pages 2302 - 2313 | - |
| DESCRIPTION | - MARTY et al., J Clin Oncol., (20050000), vol. 23, no. 19, pages 4265 - 4274 | - |
| DESCRIPTION | - MARTY et al., J Clin Oncol, (20050000), vol. 23, pages 4265 - 74 | - |
| DESCRIPTION | - OLAYIOYE et al., EMBO J, (20000000), vol. 19, pages 3159 - 67 | - |
| DESCRIPTION | - PARKIN, D, Oncogene, (20040000), vol. 23, pages 6329 - 40 | - |
| DESCRIPTION | - PARK YHKIM BSRYOO BY et al., Br J Cancer, (20060000), vol. 94, pages 959 - 63 | - |
| DESCRIPTION | - PARK YKIM BRYOO B et al., Proc Am Soc Clin Oncol, (20060000), vol. 24 | - |
| DESCRIPTION | - PINKAS-KRAMARSKI et al., EMBO J., (19960000), vol. 15, pages 2452 - 67 | - |
| DESCRIPTION | - PLOWMAN et al., Proc. Natl. Acad. Sci., (19930000), vol. 90, pages 1746 - 1750 | - |
| DESCRIPTION | - PORTERA et al., "ASCO Annual Meeting Proceedings Part I", J Clin Oncol,, (20070620), vol. 25, no. 18S, page 1028 | - |
| DESCRIPTION | - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596 | - |
| DESCRIPTION | - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623 | - |
| DESCRIPTION | - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327 | - |
| DESCRIPTION | - RIESE et al., Mol Cell Biol, (19950000), vol. 15, pages 5770 - 6 | - |
| DESCRIPTION | - ROBERT et al., J. Clin. Oncol., (20060000), vol. 24, pages 2786 - 2792 | - |
| DESCRIPTION | - ROUGIER PDUCREUX MMABJOUBI M et al., Eur J Cancer, (19940000), vol. 30, pages 1263 - 1269 | - |
| DESCRIPTION | - SAKAMOTO JCHIN KKONDO K et al., Anti-Cancer Drugs, (20060000), vol. 17, pages 2331 - 6 | - |
| DESCRIPTION | - SCHIER et al., Gene, (19950000), vol. 169, pages 147 - 155 | - |
| DESCRIPTION | - SEMBA et al., PNAS (USA), (19850000), vol. 82, pages 6497 - 6501 | - |
| DESCRIPTION | - SIAS, J. Immunol. Methods, (19900000), vol. 132, pages 73 - 80 | - |
| DESCRIPTION | - SLAMON et al., N Engl J Med., (20010000), vol. 344, no. 1 1, pages 783 - 792 | - |
| DESCRIPTION | - SLAMON et al., Science, (19870000), vol. 235, pages 177 - 182 | - |
| DESCRIPTION | - SLAMON et al., Science, (19890000), vol. 244, pages 707 - 712 | - |
| DESCRIPTION | - SLIWKOWSKI et al., J. Biol. Chem., (19940000), vol. 269, no. 20, pages 14661 - 14665 | - |
| DESCRIPTION | - SLIWKOWSKI, Nat Struct Biol, (20030000), vol. 10, pages 158 - 9 | - |
| DESCRIPTION | - STANCOVSKI et al., PNAS (USA), (19910000), vol. 88, pages 8691 - 8695 | - |
| DESCRIPTION | - STEFFENSEN et al., Int J Oncol, (20080000), vol. 33, pages 195 - 204 | - |
| DESCRIPTION | - TANNER et al., Am. J. Pathol., (20000000), vol. 157, no. 5, pages 1467 - 1472 | - |
| DESCRIPTION | - TANNER et al., J Clin Oncol, (20060000), vol. 24, pages 4317 - 23 | - |
| DESCRIPTION | - THERASSE et al., J Natl Ca Inst, (20000000), vol. 92, no. 3, pages 205 - 216 | - |
| DESCRIPTION | - THERASSE et al., J Natl Cancer Inst, (20000000), vol. 92, pages 205 - 16 | - |
| DESCRIPTION | - VANHOEFER UWAGNER TLUTZ M et al., Eur J Cancer, (20010000), vol. 37 | - |
| DESCRIPTION | - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536 | - |
| DESCRIPTION | - YAMAMOTO et al., Nature, (19860000), vol. 321, pages 522 - 525 | - |
| DESCRIPTION | - YARDENSLIWKOWSK, Nat Rev Mol Cell Biol, (20010000), vol. 2, pages 127 - 37 | - |
| EXAMINATION | - ANDERSSON MICHAEL ET AL, "Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 JAN 2011, (20110120), vol. 29, no. 3, ISSN 1527-7755, pages 264 - 271 | - |
| EXAMINATION | - COUDERT BRUNO P ET AL, "Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 01 JUL 2007, (20070701), vol. 25, no. 19, ISSN 1527-7755, pages 2678 - 2684 | - |
| EXAMINATION | - "Ellence / Epirubicin Hydrochloride Injection", HIGHLIGHTS OF PRESCRIBIN INFORMATION, (201107), pages 1 - 16 | - |
| EXAMINATION | - ROBERT NICHOLAS ET AL, "Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 JUN 2006, (20060620), vol. 24, no. 18, doi:10.1200/JCO.2005.04.1764, ISSN 1527-7755, pages 2786 - 2792, XP055686426 | |
| EXAMINATION | - Joensuu Heikki ET AL, "Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial", Journal of Clinical Oncology, US, (20091201), vol. 27, no. 34, doi:10.1200/JCO.2008.21.4577, ISSN 0732-183X, pages 5685 - 5692, XP093138336 | |
| EXAMINATION | - BASELGA JOSÉ ET AL, "Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 01 MAR 2010, (20100301), vol. 28, no. 7, doi:10.1200/JCO.2009.24.2024, ISSN 1527-7755, pages 1138 - 1144, XP055029441 | |
| OPPOSITION | - Anonymous, "Breast Cancer Treatment Guidelines for Patients", Breast Cancer Treatment Guidelines for Patients version VIII, American Cancer Society and NCCN, pages 1 - 92, Breast Cancer Treatment Guidelines for Patients version VIII, URL: https://screening.iarc.fr/doc/Breast_VIII.pdf, (20200428), XP055689834 | - |
| OPPOSITION | - Anonymous, "concomitantly and concurrently", Collins English Dictionary, (20040101), pages 332 - 333, ISBN 0-00-716334-7, XP009561639 | - |
| OPPOSITION | - Anonymous, "Definition of early-stage breast cancer", NCI Dictionary of Cancer Terms, NCI, pages 1 - 1, NCI Dictionary of Cancer Terms, URL: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/early-stage-breast-cancer, XP093288866 | - |
| OPPOSITION | - Anonymous, "Early-Stage Breast Cancer More Deadly in Men Than Women", breastcancer.org, page 1, breastcancer.org, URL: https://www.breastcancer.org/research-news/20070509, (20200429), XP055690209 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00976989", URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V_27=View, (20200717), XP055715914 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00976989", URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V_29=View, (20200717), XP055715916 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00976989", URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V_2=View, (20200717), XP055715919 | - |
| OPPOSITION | - Anonymous, "Nine months YTD 2011 sales Committed to innovation and profitable growth", Roche Nine months YTD 2011 sales, Roche, pages 1 - 142, Roche Nine months YTD 2011 sales, URL: https://web.archive.org/web/20130319020845/http://www.roche.com/irp3q11e.pdf, XP093288859 | - |
| OPPOSITION | - Anonymous, "Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Wom", FierceBiotech, pages 1 - 4, FierceBiotech, URL: https://www.fiercebiotech.com/biotech/pertuzumab-and-herceptin-plus-chemotherapy-significantly-improved-rate-of-complete-tumor, (20200511), XP055693525 | - |
| OPPOSITION | - D19 - Intermediate Opinion OD of parent patent (EP2766040B1) 17 February 2021 | - |
| OPPOSITION | - D28 - Patentee’s Submissions of 16 November 2020 in connection with Opposition to EP2766040 | - |
| OPPOSITION | - D5 - Details of relationship between Genentech, Inc. and F. Hoffmann-La Roche AG | - |
| OPPOSITION | - D9 - patentee’s submission of 22 May 2024 in prosecution | - |
| OPPOSITION | - Hoffmann-La Roche, "NCT00545688 | A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.", ClinicalTrials.gov, NLM, pages 1 - 20, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT00545688?tab=history&a=49#version-content-panel, XP093288817 | - |
| OPPOSITION | - Pellegrino Krysta , "Genentech to Present Important New Data for HER2-Positive Breast Cancer at 2011 San Antonio Breast Cancer Symposium | ", Media release, Genentech, Fierce Biotech, pages 1 - 3, Media release, URL: https://www.fiercebiotech.com/biotech/genentech-to-present-important-new-data-for-her2-positive-breast-cancer-at-2011-san-antonio, XP093288856 | - |
| OPPOSITION | - Roche Registration Gmbh, "Perjeta 420 mg concentrate for solution for infusion", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, EMA - European Medicines Agency, pages 1 - 28, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta, XP093288785 | - |
| OPPOSITION | - Roche, "Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium", Roche Media Release, Roche Media Release, URL: https://www.roche.com/dam/icr:e32f53c2-251c-4432-8bf6-32fa5efc0764/en/med-cor-2011-11-30-e.pdf, (20200415), XP055685954 | - |
| OPPOSITION | - Gokhan Ozyigit, Murat Beyzadeoglu, Cuneyt Ebruli , "Breast Cancer", Basic Radiation Oncology, Berlin, Heidelberg, Springer, (20100628), pages 329 - 361, doi:10.1007/978-3-642-11666-7_7, ISBN 978-3-642-11665-0, XP009561641 | |
| OPPOSITION | - Eugene R. Ahn; Charles L. Vogel, "Dual HER2-targeted approaches in HER2-positive breast cancer", Breast Cancer Research and Treatment, Kluwer Academic Publishers, Bo, Bo , (20110929), vol. 131, no. 2, doi:10.1007/s10549-011-1781-y, ISSN 1573-7217, pages 371 - 383, XP019994873 | |
| OPPOSITION | - Von Minckwitz Gunter, Loibl Sibylle, Maisch Andrea, Untch Michael, "Incorporating Agents that Target HER2 in the Neoadjuvant Setting", Current Breast Cancer Reports, Springer US, Boston, Boston , (20111201), vol. 3, no. 4, doi:10.1007/s12609-011-0054-4, ISSN 1943-4588, pages 190 - 196, XP093288839 | |
| OPPOSITION | - Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, De Roquancourt A, Plassa L-F, Giacchetti S, Espié M, De Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, De Thé H, Bertheau P, "Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches", British Journal of Cancer, Nature Publishing Group UK, London, London, (20110501), vol. 104, no. 11, doi:10.1038/bjc.2011.135, ISSN 0007-0920, pages 1739 - 1746, XP093288862 | |
| OPPOSITION | - Arteaga Carlos L., Sliwkowski Mark X., Osborne C. Kent, Perez Edith A., Puglisi Fabio, Gianni Luca, "Treatment of HER2-positive breast cancer: current status and future perspectives", NATURE REVIEWS CLINICAL ONCOLOGY, Nature, NY, US, NY, US , (20120101), vol. 9, no. 1, doi:10.1038/nrclinonc.2011.177, ISSN 1759-4774, pages 16 - 32, XP093288791 | |
| OPPOSITION | - A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thurlimann, H.- J. Senn, "Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Annals of Oncology, Kluwer Academic Publishers, (20110801), vol. 22, no. 8, doi:10.1093/annonc/mdr304, ISSN 09237534, pages 1736 - 1747, XP055164503 | |
| OPPOSITION | - A. Schneeweiss et al, "Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)", (20130901), vol. 24, no. 9, doi:10.1093/annonc/mdt182, pages 2278 - 2284, XP055473044 | |
| OPPOSITION | - Anonymous, "One-Two Punch with Pertuzumab & Trastuzumab Curbs Tumor Growth", Oncology Times, Lippincott Williams & Wilkins, Inc., (20090225), vol. 31, no. 4, doi:10.1097/01.COT.0000346954.76223.e3, ISSN 0276-2234, pages 9 - 10, XP093288837 | |
| OPPOSITION | - NAHTA R, HUNG M-C, SETEVA F J, "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", Cancer Research, University of Chicago Press, (20040401), vol. 64, no. 7, doi:10.1158/0008-5472.CAN-03-3856, ISSN 0008-5472, pages 2343 - 2346, XP002521223 | |
| OPPOSITION | - W. Scheuer, T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, M. Hasmann, "Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models", Cancer research, American Association for Cancer Research, (20091215), vol. 69, no. 24, doi:10.1158/0008-5472.CAN-08-4597, ISSN 00085472, pages 9330 - 9336, XP055029437 | |
| OPPOSITION | - L Gianni et al, "Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')", Cancer Research, University of Chicago Press, (20101215), vol. 70, no. 24, Suppl.2, doi:10.1158/0008-5472.SABCS10-S3-2, ISSN 0008-5472, XP009166330 | |
| OPPOSITION | - A Schneeweiss et al, "Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).", Cancer Research, University of Chicago Press, (20111215), vol. 71, no. 24, Suppl.3, doi:10.1158/0008-5472.SABCS11-S5-6, ISSN 0008-5472, XP009168120 | |
| OPPOSITION | - F. Meric-Bernstam, Hung M.-C., "Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy", Clinical cancer research, (20061101), vol. 12, no. 21, doi:10.1158/1078-0432.CCR-06-1732, ISSN 1078-0432, pages 6326 - 6330, XP055686438 | |
| OPPOSITION | - Bird Brian R.J., Swain Sandra M., "Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems", Clinical cancer research, (20080101), vol. 14, no. 1, doi:10.1158/1078-0432.CCR-07-1033, ISSN 1078-0432, pages 14 - 24, XP093288788 | |
| OPPOSITION | - Mittendorf E. A., Wu Y., Scaltriti M., Meric-Bernstam F., Hunt K. K., Dawood S., Esteva F. J., Buzdar A. U., Chen H., Eksambi S., Hortobagyi G. N., Baselga J., Gonzalez-Angulo A. M., "Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes", Clinical cancer research, (20091201), vol. 15, no. 23, doi:10.1158/1078-0432.CCR-09-1735, ISSN 1078-0432, pages 7381 - 7388, XP055777206 | |
| OPPOSITION | - Michael Untch, "Targeted Therapy for Early and Locally Advanced Breast Cancer", BREAST CARE, S. KARGER AG, BASEL, CH, CH , (20100601), vol. 5, no. 3, doi:10.1159/000315047, ISSN 1661-3791, pages 144 - 152, XP055686433 | |
| OPPOSITION | - Bruno P Coudert, Remy Largillier, Laurent Arnould, Philippe Chollet, Mario Campone, David Coeffic, Frank Priou, Joseph Gligorov, Xavier Martin, Véronique Trillet-Lenoir, Béatrice Weber, Jean Pierre Bleuse, Berangère Vasseur, Daniel Serin, Moïse Namer, "Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)- 1 Trial", Journal of Clinical Oncology, American Society of Clinical Oncology, (20070701), vol. 25, no. 19, doi:10.1200/JCO.2006.09.9994, ISSN 0732-183X, pages 2678 - 2684, XP055685976 | |
| OPPOSITION | - Anonymous K. A., Fumoleau P., Verma S., Wardley A. M., Conte P. F., Miles D., Gianni L., Mcnally V. A., Ross G., Baselga J., "Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy | Journal of Clinical Oncology", Journal of Clinical Oncology, American Society of Clinical Oncology, (20080520), vol. 26, no. 15_suppl, doi:10.1200/jco.2008.26.15_suppl.1026, ISSN 0732-183X, pages 1026 - 1026, XP093288831 | |
| OPPOSITION | - J. Baselga et al, "Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy", Journal of Clinical Oncology, (20100301), vol. 28, no. 7, doi:10.1200/JCO.2009.24.2024, pages 1138 - 1144, XP055029441 | |
| OPPOSITION | - Mbue John E., Solimando Dominic A., Waddell J. Aubrey, "Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) for Breast Cancer", HOSPITAL PHARMACY., LIPPINCOTT, PHILADELPHIA., US, US , (20080601), vol. 43, no. 6, doi:10.1310/hpj4306-462, ISSN 0018-5787, pages 462 - 468, XP093288822 | |
| OPPOSITION | - Jahanzeb Mohammad, "Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer", Clinical Breast Cancer, CIG Media Group, LP, US, US , (20080801), vol. 8, no. 4, doi:10.3816/CBC.2008.n.037, ISSN 1526-8209, pages 324 - 333, XP093202825 | |
| OPPOSITION | - Abair Tristin, O'shaughnessy Joyce, "The Clinical Utility of HER2-Targeted Therapy in the Neoadjuvant Setting: Recent Results From the San Antonio Breast Cancer Symposium", Clinical Breast Cancer, CIG Media Group, LP, US, US , (20110201), vol. 11, no. 1, doi:10.3816/CBC.2011.n.003, ISSN 1526-8209, pages 15 - 19, XP093288843 | |
| OPPOSITION | - Heller W., Mazhar D., Ward R., Sinnett H., Lowdell C., Phillips R., Shousha S., Fayaz A., Palmieri C., Coombes R., "Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer", Oncology Reports, National Hellenic Research Foundation, (20070101), vol. 17, no. 1, doi:10.3892/or.17.1.253, ISSN 1021-335X, pages 253 - 259, XP093288819 | |
| SEARCH | - Anonymous, "Assessment report for Herceptin (trastuzumab)", (20111117), pages 1 - 58, URL: https://www.ema.europa.eu/en/documents/variation-report/herceptin-h-c-278-ii-0057-epar-assessment-report-variation_en.pdf, (20230808), XP093071985 [YP] 1-8 * pages 26-27 * | - |
| SEARCH | [ ] - Anonymous, "History of Changes for Study: NCT00976989", (20090917), URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V_2=View, (20200717), XP055715919 [ ] * whole document, in particular study description, experimental arm A; * | - |
| SEARCH | - Anonymous, "History of Changes for Study: NCT00976989", (20111115), URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V_29=View, (20200717), XP055715916 [XP] 1,2,7,8 * whole document, in particular official title; study description, experimental arm A; outcome measures * [Y] 3-6 | - |
| SEARCH | - EUGENE R AHN ET AL, "Dual HER2-targeted approaches in HER2-positive breast cancer", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20110929), vol. 131, no. 2, doi:10.1007/S10549-011-1781-Y, ISSN 1573-7217, pages 371 - 383, XP019994873 [A] 1-8 * abstract * | |
| SEARCH | - L. GIANNI ET AL, "Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE)", THE BREAST, (20110301), vol. 20, no. Suppl. 1, doi:10.1016/S0960-9776(11)70241-7, page S73, XP055687184 [Y] 1-8 * abstract * | |
| SEARCH | - GNANT MICHAEL ET AL, "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial", LANCET ONCOL, (20110604), vol. 12, doi:10.1016/S1470-2045(11)70122-X, pages 631 - 641, XP093072149 [A] 1-8 * title, abstract * | |
| SEARCH | - MUSS HYMAN B. ET AL, "Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, US, vol. 360, no. 20, doi:10.1056/NEJMoa0810266, ISSN 0028-4793, (20090514), pages 2055 - 2065, URL: https://www.nejm.org/doi/pdf/10.1056/NEJMoa0810266, XP093072165 [A] 1-8 * title, abstract * | |
| SEARCH | - D. LENIHAN ET AL, "Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab", ANNALS OF ONCOLOGY, (20110610), vol. 23, no. 3, doi:10.1093/annonc/mdr294, ISSN 0923-7534, pages 791 - 800, XP055056836 [A] 1-8 * epub 10 June 2011 abstract, pages 798-799 * | |
| SEARCH | - GIANNI L ET AL, "Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20101215), vol. 70, no. 24, Suppl.2, ISSN 0008-5472, XP009166330 [A] 1-8 * abstract * | |
| SEARCH | - SCHNEEWEISS A ET AL, "Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA)", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20111215), vol. 71, no. 24, Suppl.3, ISSN 0008-5472, XP009168120 [XP] 1-8 * abstract * | |
| SEARCH | - C. C. PORTERA ET AL, "Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer", CLINICAL CANCER RESEARCH, (20080501), vol. 14, no. 9, doi:10.1158/1078-0432.CCR-07-4636, ISSN 1078-0432, pages 2710 - 2716, XP055056840 [A] 1-8 * abstract, material & methods * | |
